Crohn’s Disease Pipeline Assessment (2023) Covering Clinical Trials, Emerging Therapies, FDA, EMA, and PMDA Approvals | Janssen, RedHill Biopharma, Gilead, Galapagos, Eilly Lilly, Takeda

June 01 08:18 2023
Crohn's Disease Pipeline Assessment (2023) Covering Clinical Trials, Emerging Therapies, FDA, EMA, and PMDA Approvals | Janssen, RedHill Biopharma, Gilead, Galapagos, Eilly Lilly, Takeda
Delveinsight Business Research LLP
As per DelveInsight’s assessment, globally, about 90+ key pharma and biotech companies are working on 90+ pipeline drugs in the Crohn’s Disease therapeutics landscape based on different Routes of Administration (ROA), Mechanism of Action (MOA), and molecule types. Several of the therapies are in the advanced stages of clinical development and are expected to launch in the coming years.

Crohn’s Disease Pipeline Insight, 2023” report by DelveInsight outlines a comprehensive assessment of the present clinical/non-clinical development activities and growth prospects across the Crohn’s Disease Market. 

The Crohn’s Disease Pipeline report embraces in-depth commercial, regulatory, and Crohn’s Disease clinical trial assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the emerging Crohn’s Disease drugs, including the mechanism of action, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers, acquisition, funding, designations, and other product-related details.

Crohn’s Disease Pipeline Analysis

The report provides insights into: 

  • The report provides detailed insights into the emerging therapies for Crohn’s Disease treatment and the aggregate therapies developed by major pharma companies.

  • It accesses the different Crohn’s Disease therapies segmented into early-stage, mid-stage, and late-stage of clinical development.

  • It outlines the major Crohn’s Disease companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.

  • The report evaluates the Crohn’s Disease drugs that are under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 

  • It navigates the major collaborations (company-company collaborations and company-academia collaborations), licensing agreements, financing details, data presentation by the pharma giants, and regulatory approval in the Crohn’s Disease therapeutic market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, featured press releases from company/university websites, industry-specific third-party sources, etc.  

Crohn's Disease Pipeline Analysis

Analysis of Emerging Crohn’s Disease Therapies by Phases

The report covers the emerging products under different phases of clinical development like –

  • Late-stage products (Phase III)

  • Mid-stage products (Phase II)

  • Early-stage product (Phase I) 

  • Pre-clinical and Discovery stage candidates

  • Discontinued & Inactive candidates

Route of Administration

Crohn’s Disease pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

  • Oral

  • Intravenous

  • Subcutaneous

  • Intramuscular

  • Topical.

Molecule Type

Products have been categorized under various Molecule types such as

  • Monoclonal Antibody

  • Peptides

  • Polymer

  • Small molecule

  • Gene therapy

Learn How the Crohn’s Disease Treatment Outlook will Evolve with the Ongoing Clinical & Commercial Activities in the Therapeutic Market @

Crohn’s Disease Therapeutics Landscape

There are approx. 90+ key companies developing therapies for Crohn’s Disease. Currently, Janseen is leading the therapeutics market with its Crohn’s Disease drug candidates in the most advanced stage of clinical development.

Crohn’s Disease Companies Actively Working in the Therapeutic Market Include:

4D Pharma, Abbvie, Abivax, Aclaris Therapeutics, Active Biotech, Aibios Co Ltd, Akeso Biopharma, Alfasigma, Algernon Pharmaceuticals, Alpha Cancer Technologies, Amgen, Arena Pharmaceuticals, Artelo Biosciences, Assembly Biosciences, AstraZeneca, Athos Therapeutics, Atlantic Bio Sci, Atlantic Healthcare, Avexegen Therapeutics, Avobis Bio LLC, Bristol-Myers Squibb, Celgene, Celularity, Cerecor, ChemoCentryx, Chong Kun Dang Pharmaceutical Corp, Cloud Pharmaceuticals, Commence Bio Inc, Curacle, Cytocom, Denali Therapeutics, Draconis Pharma, Educell doo, Eisai, Eli Lilly and Company, Enzo Biochem Inc., Exeliom Biosciences SAS, Fast Forward Pharmaceuticals, Finch Therapeutics, Gilead Sciences, GlaxoSmithKline, HAV Vaccines Ltd, Hoffmann-La Roche, Iltoo Pharma, Immunic, Innovative Pharmacological Research (IPHAR) Co Ltd, Innovimmune Biotherapeutics, Intract Pharma Ltd, Janssen, JHL Biotech, Kang Stem Biotech, Koutif Therapeutics, Landos Biopharma, MakScientific, Metacrine, Mitsubishi Tanabe Pharma Corporation, Morphic Therapeutic, Navidea Biopharmaceuticals, Neuclone, Orchard Therapeutics, Origo Biopharma, Pfizer, PlantPraxis, Priothera, Protagonist Therapeutics, Provention Bio, Qu Biologics, RedHill Biopharma, Reistone Biopharma Company Limited, Roche, SLA Pharma, Soligenix, Stero Biotechs, Suzhou Connect Biopharmaceuticals, Synedgen, Synlogic, TaiwanJ Pharmaceuticals, Takeda Pharmaceuticals, Temisis Therapeutics, Tetherex Pharmaceuticals, Theravance Biopharma, Thetis Pharmaceuticals, Tiziana Life Sciences, Tract Therapeutics, Trio medicines, VHsquared Ltd., Winston Pharmaceuticals, Xbrane, and others.

Emerging and Marketed Crohn’s Disease Drugs Covered in the Report Include:

  • Guselkumab: Janssen

  • RHB-104: RedHill Biopharma

  • Jyselica (Filgotinib): Gilead Sciences/ Galapagos NV

  • Mirikizumab (LY3074828): Eilly Lilly and Company

  • Entyvio (Vedolozumab): Takeda Pharmaceuticals

And Many More

Request the Sample PDF to Get a Better Understanding of the Emerging Drugs and Crohn’s Disease Companies Working in the Market @

Table of Content (TOC)

1. Report Introduction

2. Executive Summary

3. Crohn’s Disease Treatment Patterns

4. Crohn’s Disease – DelveInsight’s Analytical Perspective

5. Therapeutic Assessment

6. Crohn’s Disease Late Stage Products (Phase-III)

7. Crohn’s Disease Mid-Stage Products (Phase-II)

8. Crohn’s Disease Early Stage Products (Phase-I)

9. Pre-clinical Products and Discovery Stage Products

10. Inactive Products

11. Dormant Products

12. Crohn’s Disease Discontinued Products

13. Crohn’s Disease Product Profiles

14. Major Crohn’s Disease Companies in the Market

15. Key Products in the Crohn’s Disease Therapeutics Segment

16. Dormant and Discontinued Products

17. Crohn’s Disease Unmet Needs

18. Crohn’s Disease Future Perspectives

19. Crohn’s Disease Analyst Review  

20. Appendix

21. Report Methodology

*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.

Download Sample PDF to Explore the Key Offerings of the Report:


About DelveInsight

DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.


Other Trending Healthcare Reports By DelveInsight

Helicobacter Pylori Infections Market

“Helicobacter Pylori Infections Market Insights, Epidemiology, and Market Forecast-2032” report delivers an in-depth understanding of the historical and forecasted epidemiology as well as the Helicobacter Pylori Infections market size, share, trends, and growth analysis in the seven major markets (i.e. the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan. Moreover, it also covers the current treatment practices, emerging drugs, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the Helicobacter Pylori Infections market.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States

view more articles

About Article Author